The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease

Journal of Neurochemistry

Volumn 137, Issue 3, 2016, Pages 331-359

  Benskey, Matthew J ^a   Perez, Ruth G ^b   Manfredsson, Fredric P ^a,c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Texas Tech University Health Sciences Center El Paso   (United States)

^c Hauenstein Neuroscience Center   (United States)

Author keywords

alpha synuclein; dopamine; Lewy body; Parkinson's disease; substantia nigra; synucleinopathy

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; VIRUS VECTOR; ANTIPARKINSON AGENT;

ALPHA SYN GENE; BIOACCUMULATION; CELL FUNCTION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CELLULAR STRESS RESPONSE; DISEASE MODEL; DOPAMINERGIC TRANSMISSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; LEWY BODY; LOSS OF FUNCTION MUTATION; NEUROMODULATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SNCA GENE; SYNUCLEINOPATHY; TAUOPATHY; ANIMAL; DRUG EFFECTS; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; ANTIPARKINSON AGENTS; HUMANS; NEURONS; PARKINSON DISEASE;

EID: 84963610075     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13570     Document Type: Review

References (274)

1. Abeliovich A. A., Schmitz Y. Y., Fariñas I. I., et al,. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 14-14.
2. Adamczyk A., Solecka J., and, Strosznajder J. B., (2005) Expression of alpha-synuclein in different brain parts of adult and aged rats. J. Physiol. Pharmacol. 56, 29-37.
3. Ahmad B., Chen Y., and, Lapidus L. J., (2012) Aggregation of alpha-synuclein is kinetically controlled by intramolecular diffusion. PNAS 109, 2336-2341.
4. Ahn T. B., Kim S. Y., Kim J. Y., et al,. (2008) alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 70, 43-49.
5. Alerte T. N. M., Akinfolarin A. A., Friedrich E. E., Mader S. A., Hong C.-S., and, Perez R. G., (2008) alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice. Neurosci. Lett. 435, 24-29.
6. Alves da Costa C., Paitel E., Vincent B., and, Checler F., (2002) Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. J. Biol. Chem. 277, 50980-50984.
7. Al-Wandi A., Ninkina N., Millership S., Williamson S. J. M., Jones P. A., and, Buchman V. L., (2010) Absence of α-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice. Neurobiol. Aging 31, 796-804.
8. Appel-Cresswell S., Vilarino-Guell C., Encarnacion M., et al,. (2013) Alpha-synuclein p. H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 28, 811-813.
9. Arai K., Kato N., Kashiwado K., and, Hattori T., (2000) Pure autonomic failure in association with human alpha-synucleinopathy. Neurosci. Lett. 296, 171-173.
10. Arawaka S., Saito Y., Murayama S., and, Mori H., (1998) Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology 51, 887-889.
11. Auluck P. K., Chan H. Y. E., Trojanowski J. Q., Lee V. M. Y., and, Bonini N. M., (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865-868.
12. Baba M., Nakajo S., Tu P. H., Tomita T., Nakaya K., Lee V. M., Trojanowski J. Q., and, Iwatsubo T., (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879.
13. Barbour R., Kling K., Anderson J. P., et al,. (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener. Dis. 5, 55-59.
14. Bartels T., Choi J. G., and, Selkoe D. J., (2011) α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107-110.
15. Beach T. G., Adler C. H., Lue L., et al,. (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117, 613-634.
16. Beach T. G., Adler C. H., Sue L. I., et al,. (2010) Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 119, 689-702.
17. Bendor J. T., Logan T. P., and, Edwards R. H., (2013) The Function of α-Synuclein. Neuron 79, 1044-1066.
18. Bennett D. A., Beckett L. A., Murray A. M., Shannon K. M., Goetz C. G., Pilgrim D. M., and, Evans D. A., (1996) Prevalence of parkinsonian signs and associated mortality in a community population of older people. N. Engl. J. Med. 334, 71-76.
19. Berman S. B., and, Hastings T. G., (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73, 1127-1137.
20. Bertoncini C. W., Jung Y.-S., Fernandez C. O., Hoyer W., Griesinger C., Jovin T. M., and, Zweckstetter M., (2005) Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. PNAS 102, 1430-1435.
21. Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V., and, Greenamyre J. T., (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306.
22. Beyer K., Lao J. I., Carrato C., Mate J. L., Lopez D., Ferrer I., and, Ariza A., (2004) Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. Neuropathol. Appl. Neurobiol. 30, 601-607.
23. Beyer K., Humbert J., Ferrer A., Lao J. I., Carrato C., Lopez D., Ferrer I., and, Ariza A., (2006) Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease. NeuroReport 17, 1327-1330.
24. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A. R., Bioulac B., Brotchie J. M., and, Gross C. E., (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21, 6853-6861.
25. Bianco Lo. C., Ridet J.-L., Schneider B. L., Deglon N., and, Aebischer P., (2002) alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. PNAS 99, 10813-10818.
26. Braak H., and, Braak E., (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259.
27. Braak H., and, Braak E., (2000) Pathoanatomy of Parkinson's disease. J. Neurol. 247, II3-II10.
28. Braak H., Del Tredici K., Rüb U., de Vos R. A. I., Jansen Steur E. N. H., and, Braak E., (2003a) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211.
29. Braak H., Rüb U., Gai W. P., and, Del Tredici K., (2003b) Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural. Transm. 110, 517-536.
30. Braak H., de Vos R. A. I., Bohl J., and, Del Tredici K., (2006) Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 396, 67-72.
31. Burré J., Sharma M., Tsetsenis T., Buchman V., Etherton M. R., and, Südhof T. C., (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663-1667.
32. Burré J., Sharma M., and, Südhof T. C., (2012) Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities. J. Neurosci. 32, 15227-15242.
33. Bussell R., and, Eliezer D., (2003) A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J. Mol. Biol. 329, 763-778.
34. Cabin D. E., Shimazu K., Murphy D., et al,. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22, 8797-8807.
35. Cabin D. E., Gispert-Sanchez S., Murphy D., Auburger G., Myers R. R., and, Nussbaum R. L., (2005) Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background. Neurobiol. Aging 26, 25-35.
36. Cali T., Ottolini D., Negro A., and, Brini M., (2012) α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J. Biol. Chem. 287, 17914-17929.
37. Caughey B., and, Lansbury P. T., (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298.
38. Chandra S. S., Chen X. X., Rizo J. J., Jahn R. R., and, Südhof T. C. T., (2003) A broken alpha -helix in folded alpha -Synuclein. J. Biol. Chem. 278, 15313-15318.
39. Chandra S., Fornai F., Kwon H.-B., et al,. (2004) Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. PNAS 101, 14966-14971.
40. Chandra S., Gallardo G., Fernández-Chacón R., Schlüter O. M., and, Südhof T. C., (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123, 383-396.
41. Chartier-Harlin M.-C., Kachergus J., Roumier C., et al,. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169.
42. Chaudhuri K. R., Healy D. G., and, Schapira A., (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 3, 235-245.
43. Chen X. H., Desilva H., Pettenati M. J., Rao P. N., Stgeorgehyslop P., Roses A. D., Xia Y., Horsburgh K., Uéda K., and, Saitoh T., (1995) The human Nacp/alpha-synuclein gene-chromosome assignment to 4q21.3-Q22 and Taqi Rflp analysis. Genomics 26, 425-427.
44. Chiba-Falek O., and, Nussbaum R. L., (2001) Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum. Mol. Genet. 10, 3101-3109.
45. Chiba-Falek O., Lopez G. J., and, Nussbaum R. L., (2006) Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov. Disord. 21, 1703-1708.
46. Choong C.-J., and, Say Y.-H., (2011) Knockdown of alpha-synuclein enhances susceptibility to staurosporine-induced apoptosis in human melanoma SK-MEL 28 cells. J. Biol. Sci. 11, 135-145.
47. Chu Y., and, Kordower J. H., (2007) Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease? Neurobiol. Dis. 25, 134-149.
48. Chung C. Y., Koprich J. B., Siddiqi H., and, Isacson O., (2009) Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 29, 3365-3373.
49. Collier T. J., Kanaan N. M., and, Kordower J. H., (2011) Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat. Rev. Neurosci. 12, 359-366.
50. Collier T. J., redmond D. E., Steece-Collier K., lipton J. W., and, Manfredsson F. P., (2016) Is alpha-synuclein loss-of-function a contributor to parkinsonian pathology? Evidence from non-human primates. Front. Neurosci. 10, 1-7.
51. Conway K. A., Harper J. D., and, Lansbury P. T., (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318-1320.
52. Conway K. A., Rochet J. C., Bieganski R. M., and, Lansbury P. T., (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346-1349.
53. Cookson M. R., (2006) Hero versus antihero: the multiple roles of alpha-synuclein in neurodegeneration. Exp. Neurol. 199, 238-242.
54. Cronin K. D., Ge D., Manninger P., Linnertz C., et al,. (2009) Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum. Mol. Genet. 18, 3274-3285.
55. Cuervo A. M., Stefanis L., Fredenburg R., Lansbury P. T., and, Sulzer D., (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292-1295.
56. Dächsel J. C., Lincoln S. J., Gonzalez J., Ross O. A., Dickson D. W., and, Farrer M. J., (2007) The ups and downs of alpha-synuclein mRNA expression. Mov. Disord. 22, 293-295.
57. Dauer W., and, Przedborski S., (2003) Parkinson's Disease: mechanisms and models. Neuron 39, 889-909.
58. Dauer W., Kholodilov N., Vila M., et al,. (2002) Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. PNAS 99, 14524-14529.
59. Davidson W. S., Jonas A., Clayton D. F., and, George J. M., (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449.
60. Decressac M., Mattsson B., Lundblad M., Weikop P., and, Bjorklund A., (2012) Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol. Dis. 45, 939-953.
61. Desplats P., Lee H.-J., Bae E.-J., Patrick C., Rockenstein E., Crews L., Spencer B., Masliah E., and, Lee S.-J., (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. PNAS 106, 13010-13015.
62. Dettmer U., Newman A. J., Luth E. S., Bartels T., and, Selkoe D., (2013) In vivo cross-linking reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-neural cells. J. Biol. Chem. 288, 6371-6385.
63. Dettmer U., Newman A. J., von Saucken V. E., Bartels T., and, Selkoe D., (2015) KTKEGV repeat motifs are key mediators of normal a-synuclein tetramerization: their mutation causes excess monomers and neurotoxicity. Proc. Natl Acad. Sci. 112, 9596-9601.
64. Dickson D. W., Fujishiro H., DelleDonne A., et al,. (2008) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 115, 437-444.
65. Dickson D. W., Fujishiro H., Orr C., DelleDonne A., Josephs K. A., Frigerio R., Burnett M., Parisi J. E., Klos K. J., and, Ahlskog J. E., (2009) Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat. Disord. 15 (Suppl 3), S1-S5.
66. Drolet R. E., Behrouz B., lookingland K. J., and, Goudreau J. L., (2004) Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 25, 761-769.
67. Dyson H. J., and, Wright P. E., (2005) Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 6, 197-208.
68. Edwards T. L., Scott W. K., Almonte C., et al,. (2010) Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet. 74, 97-109.
69. Ellis C. E., Murphy E. J., Mitchell D. C., Golovko M. Y., Scaglia F., Barceló-Coblijn G. C., and, Nussbaum R. L., (2005) Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol. Cell. Biol. 25, 10190-10201.
70. Eslamboli A., Romero-Ramos M., Burger C., Bjorklund T., Muzyczka N., Mandel R. J., Baker H., Ridley R. M., and, Kirik D., (2007) Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 130, 799-815.
71. Fares M.-B., Ait-Bouziad N., Dikiy I., et al,. (2014) The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. Hum. Mol. Genet. 23, 4491-4509.
72. Farrell K. F., Krishnamachari S., Villanueva E., Lou H., Alerte T. N. M., Peet E., Drolet R. E., and, Perez R. G., (2014) Non-motor parkinsonian pathology in aging A53T alpha-Synuclein mice is associated with progressive synucleinopathy and altered enzymatic function. J. Neurochem. 128, 536-546.
73. Farrer M., Maraganore D. M., Lockhart P., Singleton A., Lesnick T. G., de Andrade M., West A., de Silva R., Hardy J., and, Hernandez D., (2001) alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet. 10, 1847-1851.
74. Farrer M., Kachergus J., Forno L., et al,. (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55, 174-179.
75. Feany M. B., and, Bender W. W., (2000) A Drosophila model of Parkinson's disease. Nature 404, 394-398.
76. Fleming S. M., Fernagut P.-O., and, Chesselet M.-F., (2005) Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx 2, 495-503.
77. Fleming S. M., Tetreault N. A., Mulligan C. K., Hutson C. B., Masliah E., and, Chesselet M.-F., (2008) Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur. J. Neurosci. 28, 247-256.
78. Fornai F. F., Schlüter O. M. O., Lenzi P. P., et al,. (2005a) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. PNAS 102, 3413-3418.
79. Fornai F., Lenzi P., Ferrucci M., et al,. (2005b) Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Brain Res. Bull. 65, 405-413.
80. Forno L. S., (1969) Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J. Am. Geriatr. Soc. 17, 557-575.
81. Fortin D. L., Troyer M. D., Nakamura K., Kubo S., Anthony M. D., and, Edwards R. H., (2004) Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 24, 6715-6723.
82. Fortin D. L., Nemani V. M., Voglmaier S. M., Anthony M. D., Ryan T. A., and, Edwards R. H., (2005) Neural activity controls the synaptic accumulation of alpha-synuclein. J. Neurosci. 25, 10913-10921.
83. Fountaine T. M., and, Wade-Martins R., (2007) RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J. Neurosci. Res. 85, 351-363.
84. Fountaine T. M., Venda L. L., Warrick N., Christian H. C., Brundin P., Channon K. M., and, Wade-Martins R., (2008) The effect of alpha-synuclein knockdown on MPP plus toxicity in models of human neurons. Eur. J. Neurosci. 28, 2459-2473.
85. Fredenburg R. A., Rospigliosi C., Meray R. K., Kessler J. C., Lashuel H. A., Eliezer D., and, Lansbury P. T. J., (2007) The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 46, 7107-7118.
86. Fuchs J., Nilsson C., Kachergus J., et al,. (2007) Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68, 916-922.
87. Fuchs J., Tichopad A., Golub Y., Munz M., Schweitzer K. J., Wolf B., Berg D., Mueller J. C., and, Gasser T., (2008) Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J. 22, 1327-1334.
88. Galvin J. E., Uryu K., Lee V. M., and, Trojanowski J. Q., (1999) Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. PNAS 96, 13450-13455.
89. Galvin J. E., Schuck T. M., Lee V. M. Y., and, Trojanowski J. Q., (2001) Differential expression and distribution of α-, β-, and γ-synuclein in the developing human substantia nigra. Exp. Neurol. 168, 347-355.
90. Gaugler M. N., Genc O., Bobela W., et al,. (2012) Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol. 123, 653-669.
91. George J. M., (2001) The synucleins. Genome Biol. 3, 3002.1-3002.6.
92. Gertz H. J., Siegers A., and, Kuchinke J., (1994) Stability of cell size and nucleolar size in Lewy body containing neurons of substantia nigra in Parkinson's disease. Brain Res. 637, 339-341.
93. Ghosh D., Mondal M., Mohite G. M., Singh P. K., Ranjan P., Anoop A., Ghosh S., Jha N. N., Kumar A., and, Maji S. K., (2013) The Parkinson's disease-associated H50Q mutation accelerates α-Synuclein aggregation in vitro. Biochemistry 52, 6925-6927.
94. Ghosh D., Sahay S., Ranjan P., et al,. (2014) The newly discovered Parkinson's disease associated Finnish mutation (A53E) attenuates α-synuclein aggregation and membrane binding. Biochemistry 53, 6419-6421.
95. Giasson B. I., Duda J. E., Quinn S. M., Zhang B., Trojanowski J. Q., and, Lee V., (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34, 521-533.
96. Gispert S., Del Turco D., Garrett L., et al,. (2003) Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol. Cell Neurosci. 24, 419-429.
97. Goedert M., Spillantini M. G., Del Tredici K., and, Braak H., (2012) 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13-24.
98. Goedert M., Spillantini M. G., Del Tredici K., and, Braak H., (2013) 100 years of Lewy pathology. 9, 13-24.
99. Gombash S. E., Manfredsson F. P., Kemp C. J., Kuhn N. C., Fleming S. M., Egan A. E., Grant L. M., Ciucci M. R., MacKeigan J. P., and, Sortwell C. E., (2013) Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. PLoS ONE 8, e81426-e81426.
100. Gomez-Isla T., Irizarry M. C., Mariash A., et al,. (2003) Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol. Aging 24, 245-258.
101. Gorbatyuk O. S., Li S., Nash K., et al,. (2010) In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol. Ther. 18, 1450-1457.
102. Götz J., Deters N., Doldissen A., Bokhari L., Ke Y., Wiesner A., Schonrock N., and, Ittner L. M., (2007) A decade of tau transgenic animal models and beyond. Brain Pathol. 17, 91-103.
103. Graham D. G. D., Tiffany S. M. S., Bell W. R. W., and, Gutknecht W. F. W., (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14, 644-653.
104. Greten-Harrison B., Polydoro M., Morimoto-Tomita M., et al,. (2010) αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc. Natl Acad. Sci. 107, 19573-19578.
105. Gründemann J., Schlaudraff F., Haeckel O., and, Liss B., (2008) Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res. 36, e38.
106. H T. P., Galvin J. E., baba M., Giasson B., Tomita T., Leight S., Nakajo S., Iwatsubo T., Trojanowski J. Q., and, Lee V. M., (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol. 44, 415-422.
107. Häbig K., Walter M., Stappert H., Riess O., and, Bonin M., (2009) Microarray expression analysis of human dopaminergic neuroblastoma cells after RNA interference of SNCA-a key player in the pathogenesis of Parkinson's disease. Brain Res. 1256, 19-33.
108. Hallett P. J., McLean J. R., Kartunen A., Langston J. W., and, Isacson O., (2012) α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol. Dis. 47, 258-267.
109. Halliday G. M., Del Tredici K., and, Braak H., (2006) Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J. Neural Transm. Suppl. 70, 99-103.
110. Han Y., Khodr C. E., Sapru M. K., Pedapati J., and, Bohn M. C., (2011) A microRNA embedded AAV α-synuclein gene silencing vector for dopaminergic neurons. Brain Res. 1386, 15-24.
111. Hasegawa M., Fujiwara H., Nonaka T., Wakabayashi K., Takahashi H., Lee V., Trojanowski J. Q., Mann D., and, Iwatsubo T., (2002) Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J. Biol. Chem. 277, 49071-49076.
112. Hashimoto M., Hsu L. J., Xia Y., Takeda A., Sisk A., Sundsmo M., and, Masliah E., (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. NeuroReport 10, 717-721.
113. Hashimoto M., Rockenstein E., and, Masliah E., (2003) Transgenic models of alpha-synuclein pathology-Past, present, and future. Ann. N. Y. Acad. Sci. 991, 171-188.
114. Hely M. A., Morris J. G., Traficante R., Reid W. G., O'Sullivan D. J., and, Williamson P. M., (1999) The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J. Neurol. Neurosurg. Psychiatr. 67, 300-307.
115. Hermida-Ameijeiras A., Méndez-Alvarez E., Sánchez-Iglesias S., Sanmartín-Suárez C., and, Soto-Otero R., (2004) Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. Neurochem. Int. 45, 103-116.
116. Hoffman-Zacharska D., Koziorowski D., Ross O. A., et al,. (2013) Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson's disease. Parkinsonism Relat. Disord. 19, 1057-1060.
117. Höglinger G. U., Carrard G., Michel P. P., Medja F., Lombès A., Ruberg M., Friguet B., and, Hirsch E. C., (2003) Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J. Neurochem. 86, 1297-1307.
118. Hong D.-P., Xiong W., Chang J.-Y., and, Jiang C., (2011) The role of the C-terminus of human alpha-synuclein: intra-disulfide bonds between the C-terminus and other regions stabilize non-fibrillar monomeric isomers. FEBS Lett. 585, 561-566.
119. Hutton M., Lendon C. L., Rizzu P., et al,. (1998) Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705.
120. Ibanez P., Bonnet A.-M., Debarges B., Lohmann E., Tison F., Pollak P., Agid Y., Durr A., Brice A., and, Group F. P. D. S., (2004) Causal relation between a-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1169-1171.
121. Ikeuchi T., Kakita A., Shiga A., et al,. (2008) Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch. Neurol. 65, 514-519.
122. Iwai A., Masliah E., Yoshimoto M., Ge N. F., Flanagan L., Desilva H., Kittel A., and, Saitoh T., (1995) The precursor protein of non-a-beta component of Alzheimers-disease amyloid Is a presynaptic protein of the central-nervous-system. Neuron 14, 467-475.
123. Jakes R., Spillantini M. G., and, Goedert M., (1994) Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27-32.
124. Jang A., Lee H.-J., Suk J.-E., Jung J.-W., Kim K.-P., and, Lee S.-J., (2010) Non-classical exocytosis of a-synuclein is sensitive to folding states and promoted under stress conditions. J. Neurochem. 5, 1263-1274.
125. Jao C. C., Der-Sarkissian A., Chen J., and, Langen R., (2004) Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. PNAS 101, 8331-8336.
126. Jellinger K. A., (2008) A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol. 116, 1-16.
127. Jensen M. B., Bhatia V. K., Jao C. C., Rasmussen J. E., Pedersen S. L., Jensen K. J., Langen R., and, Stamou D., (2011) Membrane curvature sensing by amphipathic helices: a single liposome study using α-synuclein and annexin B12. J. Biol. Chem. 286, 42603-42614.
128. Kahle P. J., Neumann M., Ozmen L., et al,. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365-6373.
129. Kanaan N. M., and, Manfredsson F. P., (2012) Loss of functional alpha-synuclein: a toxic event in Parkinson's disease? J. Parkinsons Dis. 2, 249-267.
130. Khan F. H., Sen T., Maiti A. K., Jana S., Chatterjee U., and, Chakrabarti S., (2005) Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease. Biochim. Biophys. Acta 1741, 65-74.
131. Khodr C. E., Sapru M. K., Pedapati J., Han Y., West N. C., Kells A. P., Bankiewicz K. S., and, Bohn M. C., (2011) An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res. 1395, 94-107.
132. Kingsbury A. E., Daniel S. E., Sangha H., Eisen S., Lees A. J., and, Foster O. J. F., (2004) Alteration in alpha-synuclein mRNA expression in Parkinson's disease. Mov. Disord. 19, 162-170.
133. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T. E., Muzyczka N., Mandel R. J., and, Björklund A., (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780-2791.
134. Kirik D., Annett L. E., Burger C., Muzyczka N., Mandel R. J., and, Björklund A., (2003) Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. PNAS 100, 2884-2889.
135. Klein R. L., King M. A., Hamby M. E., and, Meyer E. M., (2002) Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 13, 605-612.
136. Koo H.-J., Lee H.-J., and, Im H., (2008) Sequence determinants regulating fibrillation of human α-synuclein. Biochem. Biophys. Res. Commun. 368, 772-778.
137. Kordower J. H., Chu Y., Hauser R. A., Freeman T. B., and, Olanow C. W., (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504-506.
138. Kordower J. H., Olanow C. W., Dodiya H. B., Chu Y., Beach T. G., Adler C. H., Halliday G. M., and, Bartus R. T., (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 136, 2419-2431.
139. Kosaka K., (1978) Lewy bodies in cerebral cortex, report of three cases. Acta Neuropathol. 42, 127-134.
140. Kramer M. L., and, Schulz-Schaeffer W. J., (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci. 27, 1405-1410.
141. Kruger R., Kuhn W., Müller T., Woitalla D., Graeber M., Kösel S., Przuntek H., Epplen J. T., Schöls L., and, Riess O., (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
142. Krumova P., Meulmeester E., Garrido M., et al,. (2011) Sumoylation inhibits alpha-synuclein aggregation and toxicity. J. Cell Biol. 194, 49-60.
143. Kuhn M., Haebig K., Bonin M., Ninkina N., Buchman V. L., Poths S., and, Riess O., (2007) Whole genome expression analyses of single- and double-knock-out mice implicate partially overlapping functions of alpha- and gamma-synuclein. Neurogenetics 8, 71-81.
144. Kuo Y.-M., Li Z., Jiao Y., et al,. (2010) Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum. Mol. Genet. 19, 1633-1650.
145. Lakso M., Vartiainen S., Moilanen A. M., Sirvio J., Thomas J. H., Nass R., Blakely R. D., and, Wong G., (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 86, 165-172.
146. Larsen K. E., Schmitz Y., Troyer M. D., et al,. (2006) alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci. 26, 11915-11922.
147. Lauwers E., Debyser Z., Van Dorpe J., De Strooper B., Nuttin B., and, Baekelandt V., (2003) Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol. 13, 364-372.
148. Lee F., Liu F., Pristupa Z. B., and, Niznik H. B., (2001a) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15, 916-926.
149. Lee M. H., Hyun D. H., and, Halliwell B., (2001b) Effect of the overexpression of wild-type or mutant a-synuclein on cell susceptibility to insult.-Lee-2001-Journal of Neurochemistry-Wiley Online Library. J. Neurochem. 76, 998-1009.
150. Lee M. K., Stirling W., Xu Y., Xu X., Qui D., Mandir A. S., Dawson T. M., Copeland N. G., Jenkins N. A., and, Price D. L., (2002) Human -synuclein-harboring familial Parkinson's disease-linked Ala-53 -> Thr mutation causes neurodegenerative disease with -synuclein aggregation in transgenic mice. Proc. Natl Acad. Sci. 99, 8968-8973.
151. Lee H. J., Patel S., and, Lee S. J., (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 25, 6016-6024.
152. Lee H.-J., Suk J.-E., Bae E.-J., Lee J.-H., Paik S. R., and, Lee S.-J., (2008) Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int. J. Biochem. Cell Biol. 40, 1835-1849.
153. Lee H.-J., Bae E.-J., and, Lee S.-J., (2014) Extracellular α-synuclein-a novel and crucial factor in Lewy body diseases. Nat. Rev. Neurol. 10, 92-98.
154. Lesage S., Anheim M., Letournel F., et al,. (2013) G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 73, 459-471.
155. Lewis J., Melrose H., Bumcrot D., et al,. (2008) In vivo silencing of alpha-synuclein using naked siRNA. Mol. Neurodegener. 3, 19-19.
156. Li J., Uversky V. N., and, Fink A. L., (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40, 11604-11613.
157. Li W., West N., Colla E., et al,. (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. PNAS 102, 2162-2167.
158. Li J.-Y., Englund E., Holton J. L., et al,. (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501-503.
159. Li N.-N., Mao X.-Y., Chang X.-L., Zhao D.-M., Zhang J.-H., Liao Q., Yu W.-J., Tan E.-K., and, Peng R., (2013) SNCA rs356219 variant increases risk of sporadic Parkinson's disease in ethnic Chinese. Am. J. Med. Genet. B Neuropsychiatr. Genet. 162B, 452-456.
160. Lin X., Parisiadou L., Sgobio C., et al,. (2012) Conditional expression of Parkinson's disease-related mutant a-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J. Neurosci. 32, 9248-9264.
161. Linnertz C., Saucier L., Ge D., Cronin K. D., Burke J. R., Browndyke J. N., Hulette C. M., Welsh-Bohmer K. A., and, Chiba-Falek O., (2009) Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS ONE 4, e7480.
162. Lippa C. F., Fujiwara H., Mann D. M., et al,. (1998) Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 153, 1365-1370.
163. Liu D., Jin L., Wang H., et al,. (2008) Silencing alpha-synuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells. Neurochem. Res. 33, 1401-1409.
164. Lotharius J., and, O'Malley K. L., (2000) The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275, 38581-38588.
165. Lou H., Montoya S. E., Alerte T. N. M., et al,. (2010) Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J. Biol. Chem. 285, 17648-17661.
166. Luk K. C., Song C., O'Brien P., Stieber A., Branch J. R., Brunden K. R., Trojanowski J. Q., and, Lee V. M. Y., (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. 106, 20051-20056.
167. Luk K. C., Kehm V. M., Zhang B., O'Brien P., Trojanowski J. Q., and, Lee V. M. Y., (2012a) Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J. Exp. Med. 209, 975-986.
168. Luk K. C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J. Q., and, Lee V. M. Y., (2012b) Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953.
169. Lundblad M., Decressac M., Mattsson B., and, Björklund A., (2012) Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. PNAS 109, 3213-3219.
170. Mak S. K., McCormack A. L., Langston J. W., Kordower J. H., and, Di Monte D. A., (2009) Decreased alpha-synuclein expression in the aging mouse substantia nigra. Exp. Neurol. 220, 359-365.
171. Manning-Bog A. B., McCormack A. L., Li J., Uversky V. N., Fink A. L., and, Di Monte D. A., (2002) The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277, 1641-1644.
172. Maraganore D. M., de Andrade M., Elbaz A., et al,. (2006) Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 296, 661-670.
173. Markopoulou K., Biernacka J. M., Armasu S. M,. et al. (2014) Does a-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease? Parkinsonism Relat. Disord. 20, 584-589-discussion 584.
174. Maroteaux L., Campanelli J. T., and, Scheller R. H., (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804-2815.
175. Marti M. J., Tolosa E., and, Campdelacreu J., (2003) Clinical overview of the synucleinopathies. Mov. Disord. 18, S21-S27.
176. Martinez J., Moeller I., Erdjument-Bromage H., Tempst P., and, Lauring B., (2003) Parkinson's disease-associated alpha-synuclein is a calmodulin substrate. J. Biol. Chem. 278, 17379-17387.
177. Marui W., Iseki E., Nakai T., Miura S., Kato M., Uéda K., and, Kosaka K., (2002) Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J. Neurol. Sci. 195, 153-159.
178. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., and, Mucke L., (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269.
179. Matsuoka Y., Vila M., Lincoln S., et al,. (2001) Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8, 535-539.
180. McCormack A. L., Mak S. K., Henderson J. M., Bumcrot D., Farrer M. J., and, Di Monte D. A., (2010) Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS ONE 5, e12122-e12122.
181. McLean J. R., Hallett P. J., Cooper O., Stanley M., and, Isacson O., (2012) Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol. Cell Neurosci. 49, 230-239.
182. Middleton E. R., and, Rhoades E., (2010) Effects of curvature and composition on alpha-synuclein binding to lipid vesicles. Biophys. J. 99, 2279-2288.
183. Miller D. W., Hague S. M., Clarimon J., Baptista M., Gwinn-Hardy K., Cookson M. R., and, Singleton A. B., (2004) Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62, 1835-1838.
184. Miller D. W., Johnson J. M., Solano S. M., Hollingsworth Z. R., Standaert D. G., and, Young A. B., (2005) Absence of α-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J. Neural. Transm. 112, 1613-1624.
185. Morris M., Maeda S., Vossel K., and, Mucke L., (2011) The many faces of tau. Neuron 70, 410-426.
186. Murphy D. D., Rueter S. M., Trojanowski J. Q., and, Lee V. M., (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214-3220.
187. Narhi L., Wood S. J., Steavenson S., et al,. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274, 9843-9846.
188. Neystat M., Lynch T., Przedborski S., Kholodilov N., Rzhetskaya M., and, Burke R. E., (1999) Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease. Mov. Disord. 14, 417-422.
189. Nishioka K., Hayashi S., Farrer M. J., et al,. (2006) Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann. Neurol. 59, 298-309.
190. Noorian A. R., Rha J., Annerino D. M., Bernhard D., Taylor G. M., and, Greene J. G., (2012) Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system. Neurobiol. Dis. 48, 9-19.
191. Olanow C. W., and, Prusiner S. B., (2009) Is Parkinson's disease a prion disorder? Proc. Natl Acad. Sci. 106, 12571-12572.
192. Osterberg V. R., Spinelli K. J., Weston L. J., Luk K. C., Woltjer R. L., and, Unni V. K., (2015) Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep. 10, 1252-1260.
193. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J., and, Wolozin B., (1999) alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19, 5782-5791.
194. Oueslati A., Fournier M., and, Lashuel H. A., (2010) Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog. Brain Res. 183, 115-145.
195. Pasanen P., Myllykangas L., Siitonen M., Raunio A., Kaakkola S., Lyytinen J., Tienari P. J., Pöyhönen M., and, Paetau A., (2014) Novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol. Aging 35 (2180), e1-e5.
196. Paumier K. L., Luk K. C., Manfredsson F. P., et al,. (2015) Intrastriatal injection of pre-formed mouse a-synuclein fibrils into rats triggers a-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol. Dis. 82, 185-199.
197. Peng X., Tehranian R., Dietrich P., Stefanis L., and, Perez R. G., (2005) alpha-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J. Cell Sci. 118, 3523-3530.
198. Perez R. G., and, Hastings T. G., (2004) Could a loss of alpha-synuclein function put dopaminergic neurons at risk? J. Neurochem. 89, 1318-1324.
199. Perez R. G., Waymire J. C., Lin E., Liu J. J., Guo F. L., and, Zigmond M. J., (2002) A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22, 3090-3099.
200. Pfeiffer R. F., (2003) Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2, 107-116.
201. Pieri L., Madiona K., Bousset L., and, Melki R., (2012) Fibrillar a-synuclein and huntingtin exon 1 assemblies are toxicto the cells. Biophys. J. 102, 2894-2905.
202. Polymeropoulos M. H., Lavedan C., Leroy E., and, Ide S. E., (1997) Mutation in the a-Synuclein Gene Identified in Families with Parkinson's Disease. Science 276, 2045-2047.
203. Porras J. L., and, Perez R. G., (2014) Potential contribution of alpha-synuclein dysregulation to Parkinson's disease pathology in Nova Publishers-Alpha-Synuclein (, Kanowitz M. P. A. H. C., ed), pp. 51-70. NY: NOVA Science Publishers.
204. van der Putten H., Wiederhold K. H., Probst A., et al,. (2000) Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20, 6021-6029.
205. Quilty M. C., King A. E., Gai W. P., Pountney D. L., West A. K., Vickers J. C., and, Dickson T. C., (2006) Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection. Exp. Neurol. 199, 249-256.
206. Quinn J. G., Coulson D. T. R., Brockbank S., Beyer N., Ravid R., Hellemans J., Irvine G. B., and, Johnston J. A., (2012) α-Synuclein mRNA and soluble α-synuclein protein levels in post-mortem brain from patients with Parkinson"s disease, dementia with Lewy bodies, and Alzheimer"s disease. Brain Res. 1459, 71-80.
207. Richfield E. K., Thiruchelvam M. J., Cory-Slechta D. A., Wuertzer C., Gainetdinov R. R., Caron M. G., Di Monte D. A., and, Federoff H. J., (2002) Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 175, 35-48.
208. Robertson D. C., Schmidt O., Ninkina N., Jones P. A., Sharkey J., and, Buchman V. L., (2004) Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. J. Neurochem. 89, 1126-1136.
209. Rockenstein E., Mallory M., Hashimoto M., Song D., Shults C. W., Lang I., and, Masliah E., (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 68, 568-578.
210. Santacruz K., Lewis J., Spires T., et al,. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481.
211. Satake W., Nakabayashi Y., Mizuta I., et al,. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303-1307.
212. Schlüter O. M., Fornai F., Alessandri M. G., Takamori S., Geppert M., Jahn R. R., and, Südhof T. C., (2003) Role of a-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience 118, 985-1002.
213. Scott D., and, Roy S., (2012) α-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J. Neurosci. 32, 10129-10135.
214. Serpell L. C., Berriman J., Jakes R., Goedert M., and, Crowther R. A., (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. PNAS 97, 4897-4902.
215. Shannon K. M., Keshavarzian A., Dodiya H. B., Jakate S., and, Kordower J. H., (2012a) Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov. Disord. 27, 716-719.
216. Shannon K. M., Keshavarzian A., Mutlu E., Dodiya H. B., Daian D., Jaglin J. A., and, Kordower J. H., (2012b) Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov. Disord. 27, 709-715.
217. Sharon R., Goldberg M. S., Bar-Josef I., Betensky R. A., Shen J., and, Selkoe D. J., (2001) alpha-synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. PNAS 98, 9110-9115.
218. Shin E. C., Cho S. E., Lee D. K., Hur M. W., Paik S. R., Park J. H., and, Kim J., (2000) Expression patterns of alpha-synuclein in human hematopoietic cells and in Drosophila at different developmental stages. Mol. Cells 10, 65-70.
219. Shtilerman M. D., Ding T. T., and, Lansbury P. T., (2002) Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry 41, 3855-3860.
220. Simón-Sánchez J., Schulte C., Bras J. M., et al,. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308-1312.
221. Singleton A. B., Farrer M., Johnson J., et al,. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
222. Specht C. G., and, Schoepfer R., (2001) Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci. 2, 11.
223. Spillantini M. G., Schmidt M. L., Lee V., and, Trojanowski J. Q., (1997) [alpha]-Synuclein in Lewy bodies: article: nature. Nature 388, 839-840.
224. Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M., Goedert M., (1998a) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. 95, 6469-6473.
225. Spillantini M. G., Crowther R. A., Jakes R., and, Cairns N. J., (1998b) Filamentous a-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neuroscience 251, 205-208.
226. St Martin J. L., Klucken J., and, Outeiro T. F., (2007) Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J. Neurochem. 100, 1449-1457.
227. Stefanis L., (2012) Synuclein in Parkinson's Disease. Cold Spring Harb. Perspect Med. 2, a009399-a009399.
228. Surguchov A., (2008) Chapter 6 molecular and cellular biology of synucleins. Inter Rev. Cell Mol. Biol. 271, 227-282.
229. Tan E.-K., Chandran V. R., Fook-Chong S., Shen H., Yew K., Teoh M.-L., Yuen Y., and, Zhao Y., (2005) Alpha-synuclein mRNA expression in sporadic Parkinson's disease. Mov. Disord. 20, 620-623.
230. Tanner C. M., and, Goldman S. M., (1996) Tanner: epidemiology of Parkinson's disease-Google Scholar. Neurol. Clin. 14, 317-335.
231. Tehranian R., Montoya S. E., Van Laar A. D., Hastings T. G., and, Perez R. G., (2006) Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. J. Neurochem. 99, 1188-1196.
232. Theodore S., Cao S., McLean P. J., and, Standaert D. G., (2008) Targeted Overexpression of Human alpha-Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease. J. Neuropathol. Exp. Neurol. 67, 1149-1158.
233. Thiruchelvam M. J., Powers J. M., Cory-Slechta D. A., and, Richfield E. K., (2004) Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur. J. Neurosci. 19, 845-854.
234. Tofaris G. K., Reitbock P. G., Humby T., et al,. (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein (1-120): implications for Lewy body disorders. J. Neurosci. 26, 3942-3950.
235. Tompkins M. M., Basgall E. J., Zamrini E., and, Hill W. D., (1997) Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am. J. Pathol. 150, 119-131.
236. Trojanowski J. Q., and, Lee V. M. Y., (2005) Pathological tau: a loss of normal function or a gain in toxicity? Nat. Neurosci. 8, 1136-1137.
237. Ubhi K., Rockenstein E., Mante M., Inglis C., Adame A., Patrick C., Whitney K., and, Masliah E., (2010) Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J. Neurosci. 30, 6236-6246.
238. Uéda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D. A., Kondo J., Ihara Y., and, Saitoh T., (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. PNAS 90, 11282-11286.
239. Uéda K., Saitoh T., and, Mori H., (1994) Tissue-dependent alternative splicing of messenger-Rna for Nacp, the precursor of non-a-beta component of Alzheimers-disease amyloid. Biochem. Biophys. Res. Commun. 205, 1366-1372.
240. Unni V. K., Weissman T. A., Rockenstein E., Masliah E., McLean P. J., and, Hyman B. T., (2010) In vivo imaging of alpha-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility. PLoS ONE 5, e10589.
241. Uversky V. N., (2002) What does it mean to be natively unfolded? Eur. J. Biochem. 269, 2-12.
242. Uversky V. N., (2007) Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J. Neurochem. 103, 17-37.
243. Uversky V. N., and, Eliezer D., (2009) Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr. Protein Pept. Sci. 10, 483-499.
244. Uversky V. N., Li J., and, Fink A. L., (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276, 10737-10744.
245. Uversky V. N., M Cooper E., Bower K. S., Li J., and, Fink A. L., (2002) Accelerated alpha-synuclein fibrillation in crowded milieu. FEBS Lett. 515, 99-103.
246. VanderHorst V. G., Samardzic T., Saper C. B., Anderson M. P., Nag S., Schneider J. A., Bennett D. A., and, Buchman A. S., (2015) synuclein pathology accumulates in sacral spinal visceral sensory pathways. Ann. Neurol. 78, 142-149.
247. Vargas K. J., Makani S., Davis T., Westphal C. H., Castillo P. E., and, Chandra S. S., (2014) Synucleins regulate the kinetics of synaptic vesicle endocytosis. J. Neurosci. 34, 9364-9376.
248. Vargas-Medrano J., Krishnamachari S., Villanueva E., Godfrey W. H., Lou H., Chinnasamy R., Arterburn J. B., and, Perez R. G., (2014) Novel FTY720-based compounds stimulate neurotrophin expression and phosphatase activity in dopaminergic cells. ACS Med. Chem. Lett. 5, 782-786.
249. Volles M. J., Lee S. J., Rochet J. C., Shtilerman M. D., Ding T. T., Kessler J. C., and, Lansbury P. T., (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819.
250. Volpicelli-Daley L. A., Luk K. C., Patel T. P., Tanik S. A., Riddle D. M., Stieber A., Meaney D. F., Trojanowski J. Q., and, Lee V. M. Y., (2011) Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57-71.
251. Wakabayashi K., Takahashi H., Takeda S., Ohama E., and, Ikuta F., (1988) Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol. 76, 217-221.
252. Wakabayashi K., Takahashi H., Ohama E., and, Ikuta F., (1990) Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol. 79, 581-583.
253. Wakabayashi K., Takahashi H., Ohama E., Takeda S., and, Ikuta F., (1993) Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. Adv. Neurol. 60, 609-612.
254. Wakabayashi K., Yoshimoto M., Fukushima T., Koide R., Horikawa Y., Morita T., and, Takahashi H., (1999) Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenileand adult-onset Hallervorden-Spatz diseasewith Lewy bodies. Neuropathol. Appl. Neurobiol. 25, 363-368.
255. Wakamatsu M., Ishii A., Iwata S., et al,. (2008) Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol. Aging 29, 574-585.
256. Wang L., Fleming S. M., Chesselet M.F., Tache Y., (2008) Abnormal colonic motility in mice overexpressing human wild-type α-synuclein. NeuroReport 19, 873.
257. Wang J., Lou H., Pedersen C. J., Smith A. D., and, Perez R. G., (2009) 14-3-3zeta contributes to tyrosine hydroxylase activity in MN9D cells: localization of dopamine regulatory proteins to mitochondria. J. Biol. Chem. 284, 14011-14019.
258. Weinreb P. H., Zhen W., Poon A. W., Conway K. A., and, Lansbury P. T., (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709-13715.
259. Wersinger C., and, Sidhu A., (2003a) Differential cytotoxicity of dopamine and H2O2 in a human neuroblastoma divided cell line transfected with a-synuclein and its familial Parkinson's disease-linked mutants. Neurosci. Lett. 342, 124-128.
260. Wersinger C., and, Sidhu A., (2003b) Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci. Lett. 340, 189-192.
261. Wersinger C., Prou D., Vernier P., and, Sidhu A., (2003) Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J. 17, 2151.
262. Wood S. J., Wypych J., Steavenson S., Louis J. C., Citron M., and, Biere A. L., (1999) alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509-19512.
263. Woods W. S., Boettcher J. M., Zhou D. H., Kloepper K. D., Hartman K. L., Ladror D. T., Qi Z., Rienstra C. M., and, George J. M., (2007) Conformation-specific binding of alpha-synuclein to novel protein partners detected by phage display and NMR spectroscopy. J. Biol. Chem. 282, 34555-34567.
264. Wu F., Poon W. S., Lu G., Wang A., Meng H., Feng L., Li Z., and, Liu S., (2009) Alpha-synuclein knockdown attenuates MPP+ induced mitochondrial dysfunction of SH-SY5Y cells. Brain Res. 1292, 173-179.
265. Wu J., Lou H., Alerte T. N. M., Stachowski E. K., Chen J., Singleton A. B., Hamilton R. L., and, Perez R. G., (2012) Lewy like aggregation of alphansynuclein reduces protein phosphatase 2A activity. Neuroscience 207, 288-297.
266. Xu J., Kao S.-Y., Lee F. J. S., Song W., Jin L.-W., and, Yankner B. A., (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8, 600-606.
267. Xuan Q., Xu S.-L., Lu D.-H., Yu S., Zhou M., Uéda K., Cui Y.-Q., Zhang B.-Y., and, Chan P., (2011) Increased expression of α-synuclein in aged human brain associated with neuromelanin accumulation. J. Neural. Transm. 118, 1575-1583.
268. Yamada M., Iwatsubo T., and, Mizuno Y., (2004) Overexpression of a-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of a-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J. Neurochem. 91, 451-461.
269. Yu S., Zuo X. H., Li Y. H., Zhang C., Zhou M., Zhang Y. A., Uéda K., and, Chan P., (2004) Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells. Neurosci. Lett. 367, 34-39.
270. Yuan Y., Sun J., Zhao M., Hu J., Wang X., Du G., and, Chen N. H., (2010) Overexpression of alpha-synuclein down-regulates BDNF expression. Cell. Mol. Neurobiol. 30, 939-946.
271. Zarranz J. J., Alegre J., Gómez-Esteban J. C., et al,. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173.
272. Zhang Bin., Maiti A., Shively S., et al,. (2005) Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. PNAS 102, 227-231.
273. Zharikov A. D., Cannon J. R., Tapias V., Bai Q., Horowitz M. P., Shah V., El Ayadi A., Hastings T. G., Greenamyre J. T., and, Burton E. A., (2015) shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. J. Clin. Invest. 125, 2721-2735.
274. Zourlidou A., Smith M. D. P., and, Latchman D. S., (2003) Modulation of cell death by alpha-synuclein is stimulus-dependent in mammalian cells. Neurosci. Lett. 340, 234-238.